Section Arrow
Quote
ATRA.NASDAQ
- Atara Biotherapeutics Inc.
Quotes are at least 15-min delayed:2025/11/16 01:02 EST
Regular Hours
Last
 13.76
+0.37 (+2.76%)
Day High 
14.28 
Prev. Close
13.39 
1-M High
16.28 
Volume 
43.93K 
Bid
11.4
Ask
15.75
Day Low
13.13 
Open
13.19 
1-M Low
10.5 
Market Cap 
94.04M 
Currency USD 
P/E 18.6 
%Yield -- 
10-SMA 12.61 
20-SMA 13.74 
50-SMA 13.64 
52-W High 18.705 
52-W Low 5.005 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.72/-0.34
Enterprise Value
123.95M
Balance Sheet
Book Value Per Share
-4.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
128.94M
Operating Revenue Per Share
0.65
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 01:02 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.